NCT06150352 · RECRUITING
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
This trial is studying whether treating obstructive sleep apnea with CPAP or similar devices helps slow cognitive decline in people who already notice memory or thinking problems. Researchers will use brain imaging to track amyloid buildup alongside cognitive testing. The phase is unspecified, meaning this appears to be an observational and interventional study exploring associations rather than a late-stage efficacy trial. Details on study design are somewhat limited.
You may qualify if
- Aged 50 - 80 years
- Diagnosis of mild cognitive impairment based on Peterson's criteria.
- Diagnosis of subjective cognitive impairment, based on the subjective complaint of cognitive impairment, but with an unremarkable assessment of the Hong Kong version of Montreal cognitive Assessment scores
- Able to speak and read Chinese
- Adequate visual and auditory to perform a cognitive test
- Subjects with moderate-severe OSA or No OSA (diagnosis based on sleep study) would be invited for baseline PET-MRI brain scan
You're excluded if
- Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder.
- Other clear organic causes of cognitive impairment, e.g. vascular cognitive impairment, brain tumour, dementia with Lewy body, mild cognitive impairment with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse.
- Diagnosis of cancer on active treatment
- Contraindications to PET-CT or MRI brain scan (excluded for neuroimaging studies)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-04-02